The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs.
Herpes simplex virus (HSV) infections are common but there is no vaccine available. We evaluated cationic liposome-DNA complexes (CLDC) as an adjuvant for an HSV gD2 vaccine and compared it to an MPL/Alum adjuvant in a guinea pig model of genital herpes. The addition of CLDC to the gD2 vaccine significantly decreased acute and recurrent disease and most importantly the number of days with recurrent virus shedding compared to gD2 alone. Reductions in these outcomes were also detected when gD2+CLDC was compared to gD2+MPL/Alum. When the vaccine and adjuvants were evaluated as therapeutic vaccines, they were ineffective. CLDC enhanced protection compared to MPL/Alum and is the first vaccine to reduce recurrent virus shedding, a key to decreasing the spread of HSV-2.
Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH, USA. David.Bernstein@cchmc.org <David.Bernstein@cchmc.org>
David I
DI
Bernstein
Nicholas
N
Farley
Fernando J
FJ
Bravo
Julie
J
Earwood
Monica
M
McNeal
Jeff
J
Fairman
Rhonda
R
Cardin
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000534:Alum Compounds / Q000494:pharmacology; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D005260:Female; D006168:Guinea Pigs; D006558:Herpes Genitalis / Q000276:immunology / Q000517:prevention & control*; D022301:Herpes Simplex Virus Vaccines / Q000276:immunology*; D018258:Herpesvirus 2, Human / Q000276:immunology; D008081:Liposomes / Q000276:immunology; D014759:Viral Envelope Proteins / Q000276:immunology*; D017201:Virus Shedding
D000276:Adjuvants, Immunologic; D000534:Alum Compounds; D000914:Antibodies, Viral; D022301:Herpes Simplex Virus Vaccines; D008081:Liposomes; D014759:Viral Envelope Proteins; C040570:glycoprotein D-herpes simplex virus type 2; C041524:aluminum sulfate